These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25053386)

  • 21. Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.
    Pestieau SR; Belliveau JF; Griffin H; Stuart OA; Sugarbaker PH
    J Surg Oncol; 2001 Feb; 76(2):106-14. PubMed ID: 11223836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.
    Elias D; El Otmany A; Bonnay M; Paci A; Ducreux M; Antoun S; Lasser P; Laurent S; Bourget P
    Oncology; 2002; 63(4):346-52. PubMed ID: 12417789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lessons learned from hyponatremia associated with hyperthermic intraperitoneal chemoperfusion with oxaliplatin.
    Nguyen MK
    Perit Dial Int; 2008; 28(1):32-4. PubMed ID: 18178945
    [No Abstract]   [Full Text] [Related]  

  • 24. Systemic exposure of the parent drug oxaliplatin during hyperthermic intraperitoneal perfusion.
    Mahteme H; Wallin I; Glimelius B; Påhlman L; Ehrsson H
    Eur J Clin Pharmacol; 2008 Sep; 64(9):907-11. PubMed ID: 18563401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
    McConnell YJ; Mack LA; Francis WP; Ho T; Temple WJ
    J Surg Oncol; 2013 May; 107(6):591-6. PubMed ID: 23129533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
    Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
    J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival prognostic factors in patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy: a single institution experience.
    Nikolic S; Dzodic R; Zegarac M; Djurisic I; Gavrilovic D; Vojinovic V; Kocic M; Santrac N; Radlovic P; Radosavljevic D; Pupic G; Martinovic A
    J BUON; 2014; 19(1):66-74. PubMed ID: 24659645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutrophil dynamics in peritoneal carcinomatosis patients treated with cytoreductive surgery and hyperthermic intraperitoneal oxaliplatin.
    Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
    Clin Pharmacokinet; 2013 Dec; 52(12):1111-25. PubMed ID: 23828617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis.
    Cattel L; De Simone M; Passera R; Verlengo MC; Delprino L
    Anticancer Res; 2004; 24(3b):2041-5. PubMed ID: 15274398
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy.
    Mehta AM; Van den Hoven JM; Rosing H; Hillebrand MJ; Nuijen B; Huitema AD; Beijnen JH; Verwaal VJ
    Int J Pharm; 2015 Feb; 479(1):23-7. PubMed ID: 25535649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
    Hompes D; D'Hoore A; Wolthuis A; Fieuws S; Mirck B; Bruin S; Verwaal V
    J Surg Oncol; 2014 May; 109(6):527-32. PubMed ID: 24375059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heated intra-operative intraperitoneal oxaliplatin plus irinotecan after complete resection of peritoneal carcinomatosis: pharmacokinetics, tissue distribution and tolerance.
    Elias D; Matsuhisa T; Sideris L; Liberale G; Drouard-Troalen L; Raynard B; Pocard M; Puizillou JM; Billard V; Bourget P; Ducreux M
    Ann Oncol; 2004 Oct; 15(10):1558-65. PubMed ID: 15367418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
    Cotte E; Colomban O; Guitton J; Tranchand B; Bakrin N; Gilly FN; Glehen O; Tod M
    J Clin Pharmacol; 2011 Jan; 51(1):9-18. PubMed ID: 20173087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.
    Jacquet P; Averbach A; Stephens AD; Stuart OA; Chang D; Sugarbaker PH
    Oncology; 1998; 55(2):130-8. PubMed ID: 9499187
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.
    Hompes D; D'Hoore A; Van Cutsem E; Fieuws S; Ceelen W; Peeters M; Van der Speeten K; Bertrand C; Legendre H; Kerger J
    Ann Surg Oncol; 2012 Jul; 19(7):2186-94. PubMed ID: 22395983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severe hyponatremia, hyperglycemia, and hyperlactatemia are associated with intraoperative hyperthermic intraperitoneal chemoperfusion with oxaliplatin.
    De Somer F; Ceelen W; Delanghe J; De Smet D; Vanackere M; Pattyn P; Mortier E
    Perit Dial Int; 2008; 28(1):61-6. PubMed ID: 18178949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics.
    Morgan RJ; Doroshow JH; Synold T; Lim D; Shibata S; Margolin K; Schwarz R; Leong L; Somlo G; Twardowski P; Yen Y; Chow W; Lin P; Paz B; Chu D; Frankel P; Stalter S
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5896-901. PubMed ID: 14676112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperthermic intraperitoneal perfusion chemotherapy--views on the observed variability in oxaliplatin pharmacokinetics.
    Srinivas NR
    Eur J Clin Pharmacol; 2009 Mar; 65(3):321-2. PubMed ID: 19011850
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacodynamics of Oxaliplatin-Derived Platinum Compounds During Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Emerging Aspect Supporting the Rational Design of Treatment Protocols.
    Löffler MW; Schuster H; Zeck A; Quilitz N; Weinreich J; Tolios A; Haen SP; Horvath P; Löb S; Rammensee HG; Königsrainer I; Königsrainer A; Beckert S
    Ann Surg Oncol; 2017 Jun; 24(6):1650-1657. PubMed ID: 28160138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis.
    Marcotte E; Sideris L; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Dubé P
    Ann Surg Oncol; 2008 Oct; 15(10):2701-8. PubMed ID: 18654822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.